Get the most detailed up-to-date strategies for moving your products into pharmerging markets!

Suzanne Munck, FTC

At past IIR “Generic Drug Summits”, our expert speaking faculty has always provided the most valuable event of the year in terms of sharing crucial and exclusive knowledge about the compliance and commercialization hurdles that you faced on a day-to-day basis. Now more than ever, the insight that we offer in our 13th annual Business of Biosimilars and Generic Drugs conference can help your company stay on top of the latest regulatory developments while capitalizing on new and untapped markets.

Our unequaled speaking faculty this year will provide you with the market-specific case studies and commercialization tactics that you need in order to expand your product portfolio and capitalize on growing global demand! Featured speakers include:

• - Andrew Shaw, Senior Director, PKDM, Mylan presenting “Establish R&D Methods and Timetables that will Streamline your Expansion into New Markets”
• - Abdullah Baaj, CEO, Boston Oncology presenting “Getting Global Manufacturing Processes Prepared for Product Rollouts”
• - Suzanne Munck, Chief Counsel for Intellectual Property, FTC presenting "Turn Antitrust Laws to Your Advantage in the Generics and Biosimilars Marketplace"

For more about these presentations and the rest of the program, download the brochure here.

The 13th Annual Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. As a reader of this blog, you receive an exclusive discount of 25% off of the standard price when you register to join us. Simply use priority code XP1786LINK. Have any questions about the event? Feel free to contact Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |

Business of Biosimilars & Generic Drugs Session Spotlight: The World is Flat—Make Sure Your Sales Are Not—Commercializing Generics in Global and Emerging Markets

The United States and European markets are redically different when it comes to the approval and use of biosimilars.  New guidelines from the FDA in the United States should make could soon make it easier to bridge the gap and identify the market.  Not only will there be an emerging market for biosimilars in the United States, but around the world.  At Business of Biosimilars and Generic Drugs, we will help you identify emerging markets for your follow-on products: both in developing countries with populations that have just gained the capacity to purchase pharmaceuticals, and the U.S. and Europe where you can capitalize on new opportunities for generic / biosimilar versions of established drugs. It will give you the skills to match the needs of each unique market segment while answering any of their concerns about product effectiveness, quality, or point of origin.

For more information about The Business of Biosimilars and Generic Drugs taking place September 10-12, 2012 in Boston, MA, download the brochure.  As a reader of this blog, when you regsiter to join us today and mention code XP1786BLOG, you'll receive a discount of 25% off the standard rate!

Featured Session: The World is Flat—Make Sure Your Sales Are Not—Commercializing Generics in Global and Emerging Markets

Featured Speaker: Andrew Shaw, Senior Director, PKDM, MYLAN

About the session: Identify growing markets (with a particular emphasis on Latin America, Asia, and MENA) to which your business plans can adapt fastest:

• - Tactics for reassuring new audiences about the suitability and acceptability of your product
• - Choosing and training regional partners required for formulation, manufacturing, and distribution
• - The U.S. as an ‘emerging’ market – focus on new methods for branded generics and facilitated reimbursement that can find new profit sources

Share this article with your social network, just click below to share now!

Share |